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Abstract  
Objectives: The Danish Myeloma Study Group initiated a randomized, placebo-controlled, 
double-blinded phase II study to investigate the efficacy of adding clarithromycin to 
cyclophosphamide-bortezomib-dexamethasone (VCD) induction therapy in transplant eligible, 
newly diagnosed multiple myeloma patients. The study was prematurely terminated due to 
severe complications, and no effect of adding clarithromycin was found. The aim of this study 
was to compare health-related quality of life (HRQoL) between the two groups and to explore the 
coherence hereof with adverse event (AE) registration by clinicians.  
Methods: Patients completed three validated HRQoL questionnaires at inclusion, before 
cyclophosphamide priming, and two months after high-dose therapy (HDT). The mean score 
difference was interpreted by clinically relevant differences between groups. Spearman 
correlation analysis was used to compare patient-reported toxicities with AEs.   
Results: Of 58 included patients, 55 participated in the HRQoL reporting. Before 
cyclophosphamide priming, patients in the clarithromycin group reported clinically relevant 
reduced HRQoL for eleven domains with persistent reduction in four domains two months after 
HDT. Poor correlation between patient-reported toxicities and clinician-reported AEs was 
observed.  
Conclusions: Despite the premature study termination, our data demonstrate impaired HRQoL when 
clarithromycin was added to the VCD regimen. We found clear underreporting of toxicities by 
clinicians. ClinicalTrials.gov number NCT02573935 
 
Key words: Multiple myeloma, Clinical trials, Quality of life, Transplantation 
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Introduction 
Analyses of health-related quality of life (HRQoL) captured by patient-reported outcomes (PRO) are 
incorporated in most randomized phase II and III clinical cancer studies (1). Patient-experienced 
benefits and toxicities are valuable parameters for shared treatment decision-making in daily 
practice (2-4). Also, PRO data results are important from a regulatory perspective in the evaluation 
of medicinal products, which has been stated by the US Food and Drug Administration (FDA) and 
European Medicine Agency (EMA) when new drugs or drug combinations are approved (5, 6).  
HRQoL during induction therapy and high-dose chemotherapy with stem cell support (HDT) in newly 
diagnosed multiple myeloma (MM) patients has been reported in more studies (7-11). In general, 
the patients report unchanged global quality of life (QoL) during induction therapy with clinically 
meaningful deterioration in global QoL, physical functioning, and increased degree of pain and 
fatigue two weeks after HDT. Two months after HDT the patients report full recovery and further 
improvement until 12 months after HDT (12). 
The Danish Myeloma Study Group (DMSG) initiated a randomized, placebo-controlled double-
blinded phase II study to investigate the efficacy and safety of adding clarithromycin to bortezomib-
cyclophosfamide-dexamethason (VCD) induction therapy prior to HDT in newly diagnosed MM 
patients (13). Clarithromycin in combination with Lenalidomide and low-dose dexamethasone is 
been found to be an effective treatment regimen with manageable side effects in treatment naïve 
symptomatic MM patients (14). The rationale for this study, entitled the CLAIM study, was to test 
these previous findings using a randomized placebo-controlled study design with addition of patient-
reported HRQoL captured by validated PRO questionnaires. In fact, a valid investigation of HRQoL 
during an anti-myeloma regimen with addition of clarithromycin has to our knowledge never been 
published.  
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The CLAIM study was prematurely terminated on 16 September 2016, after inclusion of 58 patients, 
due to a high incidence of serious adverse events (AE) in the intervention group. Response data did 
not suggest any effect of adding clarithromycin to the VCD regimen (13). The primary objective of 
this analysis was to evaluate the patient-reported HRQoL in patients receiving clarithromycin added 
to the VCD induction therapy. The secondary objective was to compare patient-reported toxicities to 
AEs reported by clinicians.  
 
Patients and methods 
Study design 
Study details have been published previously (13). Newly diagnosed transplant-eligible MM patients 
with treatment-demanding disease according to the International Myeloma Working Group criteria 
were eligible for inclusion (15). The patients were randomized (1:1 ratio) to treatment with 
clarithromycin 500 mg orally twice daily or a matching placebo tablet for 63 days in combination 
with VCD induction therapy. The VCD regimen consisted of three 21-day cycles of subcutaneous 
bortezomib 1.3 mg/square meter (sqm) day 1, 4, 8, 11, intravenous cyclophosphamide 500 mg per 
sqm on day 1 and 8, and 40 mg dexamethasone orally on day 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle. 
After initiating the protocol an amendment was approved to include a fourth VCD cycle prior to stem 
cell harvest according to an update of the Danish National Multiple Myeloma guidelines. No changes 
were made in relation to dosage or duration of study medication or placebo with the amendment. 
The study was approved by the Danish Ethical Committee, the patients provided written informed 
consent before participation, and the trial was conducted in accordance with the principles of the 
Helsinki Declaration. 
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Health-related quality of life assessment 
For HRQoL assessment, two “European Organisation for Research and Treatment of Cancer Quality 
of life” (EORTC) questionnaires were used; the cancer specific QoL instrument QLQ-C30 (16) and the 
Multiple Myeloma module QLQ-MY20 (17). The EORTC QLQ-C30 is a validated, reliable and the most 
commonly used instrument for HRQoL measurement in clinical trials with MM patients (12, 18). The 
QLQ-C30 contains one global QoL domain, five functional domains (physical, role, emotional, 
cognitive and social) and nine symptom domains (fatigue, nausea and vomiting, pain, dyspnoea, 
insomnia, appetite loss, constipation, diarrhoea and financial difficulties) (19). The EORTC QLQ-MY20 
contains two functional domains (future perspective and body image) and two symptom domains 
(disease symptoms and side effects of treatment). Each domain was scored from 0-100 and for the 
functional and global QoL domains, a higher score means better functioning/global QoL, and for the 
symptom domains, a higher score means a higher degree of symptoms. 
For evaluation of peripheral neuropathy, the “Functional Assessment of Cancer Therapy/Gynecologic 
Oncology Group Neurotoxicity” (FACT/GOG- ntx) subscale was used, which is a single domain 11-
item questionnaire (20). The questionnaire has been validated and used previously in myeloma 
patients for evaluation of treatment-related peripheral neuropathy (21, 22). The domain was scored 
from 0-44 and a higher score means a lower degree of peripheral neuropathy.  
 
Health-related quality of life data collection procedure 
The three questionnaires were scheduled to be completed by the patients at baseline (inclusion), 
before cyclophosphamide priming and two months after HDT. The patients were encouraged to 
complete the questionnaires electronically at home via a link sent by e-mail. The Internet-based tool 
of Electronic Data Capture platform has been well accepted by haematological patients (23). The 
email with a link was sent to patients at baseline, at day 60 and 180 after inclusion. If patients did 
not complete the questionnaire within 24 hours, a reminder was sent, and in case of non-response 
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seven days after the target date, the link to the questionnaire was blocked. Patients, who were not 
willing or able to answer the questionnaires electronically, completed the questionnaires by paper at 
study visits before cyclophosphamide priming and two months after HDT.  
 
Adverse events reported by clinicians 
AEs were evaluated according to “Common Terminology Criteria of Adverse Events” (CTCAE) version 
4.0 (24) at day 1 of each VCD induction cycle, at study visits before cyclophosphamide priming and 
two months after HDT by clinicians. All unresolved AEs at the visit before cyclophosphamide priming 
were followed by the responsible clinician until the AEs were resolved.  
 
Statistical methods and handling of missing data 
Calculation of domain scores and handling of missing items were performed as described in EORTC 
and FACT scoring manuals (19, 25). For the analysis of the HRQoL mean scores results, mixed model 
for repeated measures with an unstructured covariance matrix was used. A baseline constrained 
model where baseline values are constrained to be equal across treatment groups was chosen (26). 
Due to early study termination sample size was lower than planned. Therefore the HRQoL results 
were primarily interpreted by thresholds of clinical relevance between treatment groups (27). A 
treatment group difference of ≥ 5 point was defined as clinically relevant for the EORTC domains and 
≥ 11.8 points for the FACT/GOG-ntx subscale (28, 29). 
To explore the impact of non-responses to scheduled questionnaires, sensitivity analyses of the 
results of the global QoL domain were performed using two methods (A and B). First, variables 
predicting non-responses were explored using odds ratio analyses (30-32). Variables tested for 
baseline non-responses were creatinine, hemoglobin, C-reactive protein and World Health 
Organization Performance Status (WHO PS) at baseline. For non-responses to the follow-up 
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questionnaires, grade 1-2 AE, grade 3-4 AE, postponed induction cycle (more than 42 days from day 
1 cycle 1 to day 1 cycle 3), dose reduction of bortezomib, dexamethasone or cyclophosphamide, 
were tested as predictors for non-responses. In sensitivity analysis method A, multiple imputations 
were used. Missing scores were imputed using each patients´ creatinine, hemoglobin, C-reactive 
protein, WHO PS, grade 3-4 AE, information on dose reduction of bortezomib, dexamethasone or 
cyclophosphamide, postponed induction cycle or other values of global QoL (33-35). In sensitivity 
analysis method B, we identified the non-responses in the dataset, which were timely coincident (7 
days before to 30 days after) with the previously found predictive variables for non-responses. The 
timely coincident missing scores for the non-responses were replaced by the worst possible score for 
global QoL in the dataset, and the analysis was repeated.  
Spearman correlation analysis was used to compare AEs assessed by clinicians with patient-reported 
toxicities. Cohen´s criteria for medium effect size was used to calculate the minimal important 
difference (MID) for the clinically meaningful change (0.5 x standard deviation at baseline) and a 
score change above the MID was determined as clinical meaningful to the patient (36-38). We used 
Fleiss thresholds for agreement to interpret the rho score; rho values of <0.40 were poor agreement, 
values between 0.40 and 0.75 were moderate to good agreement, and values > 0.75 were excellent 
agreement (39). 
P-values below 0.05 were considered significant. R version 3.3.3 (R Foundation for Statistical 
Computing, Vienna, Austria) and SAS version 9.4 (SAS institute, Cary, NC, USA). SAS was used for 
mixed model for repeated measures, whereas R package “mice” was used for multiple imputations.     
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Results 
Patient population and compliance  
From the time of inclusion of the first patient on 16 November 2015 until termination of the study 
on 16 September 2016, 58 patients were included. Three patients did not answer any of the 
questionnaires and were excluded from the HRQoL analysis. Of the patients included in the analysis, 
25 patients were allocated to clarithromycin and 30 patients to placebo. Patient baseline 
characteristics are presented in Table 1. 
 
The completeness rates of questionnaires were 84% in the clarithromycin group and 89 % in the 
placebo group. Mean scores at baseline and standard deviations for each domain and treatment 
group are presented in Table 2. The mean baseline scores in global QoL were imbalanced with a 
difference of 8.4 points between the two groups and a graph of change in global QoL score over time 
is presented in the supplementary appendix figure 1S. The number of patients in the study at 
baseline, before cyclophosphamide priming and two months after HDT and the number of 
completed questionnaires are presented in the CONSORT diagram in Figure 1. The main reason for 
early patient drop out was serious AEs, which was the case for four patients in the clarithromycin 
group and one patient in the placebo group.   
 
Thirty-four patients (62%) completed the questionnaires electronically, and 21 patients (38%) chose 
paper questionnaires. Since some VCD induction cycles were postponed due to complications and 
some patients were treated with four cycles of VCD, not all patients completed the follow-up 
questionnaires at the scheduled time points before cyclophosphamide priming and two months 
after HDT. The follow-up questionnaires before cyclophosphamide priming were completed with a 
median of nine days too early (range -51 to 11) for the clarithromycin group and 12 days too early 
(range -41 to 1) for the placebo group. Also, the two months after HDT assessments were completed 
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with a median of four days too early (range -36 to 45) for the clarithromycin group and one day too 
early (range -38 to 19) for the placebo group.  
 
Comparison of HRQoL between treatment groups  
HRQoL domains with a clinical relevant difference in mean change of score before 
cyclophosphamide priming are presented in  Figure 2 and the domains with no clinical relevant 
difference are presented in the supplementary appendix Figure 2S.  
 
Before cyclophosphamide priming, the patients in the clarithromycin group reported clinically 
relevant reduced global QoL, physical, role, emotional and social functioning, body image and 
increasing fatigue, insomnia, disease symptoms, side effects of treatment, and peripheral 
neuropathy compared to the patients in the placebo group. Two months after HDT the clinical 
relevant reduced HRQoL was persistent for physical, role and social functioning, and insomnia. Only 
for diarrhea and constipation before cyclophosphamide priming and for constipation two months 
after HDT, the patients receiving clarithromycin reported clinically relevant reduced symptoms 
compared to the patients receiving placebo. The mean score difference for global QoL between the 
two groups was -16.2 points (95% CI -2.6;-29.8, p=0.021) before cyclophosphamide priming and -4.9 
(95% CI -11.1; 20.8, p=0.54) two months after HDT. The p-values for comparison of mean change in 
score from baseline between the two treatment groups are presented in the supplementary 
appendix Table 1S.  
 
The only statistical significant predictor for non-responses to scheduled questionnaires was 
registration of grade 3 or 4 AEs with an odds ratio of 4.2 (p=0.03) before cyclophosphamide priming 
and 3.5 (p=0.04) two months after HDT. A table of grade 3 or 4 AEs is presented in the 
supplementary appendix, table 2S. Using multiple imputation for non-responses coincident with 
registration of grade 3 and 4 AEs (method A), the mean score differences for global QoL were -15.8 
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(95% CI-29.1; -2.6 p=0.019) before cyclophosphamide priming and -3.1 (95% CI -17.9; 11.7, p=0.68) 
two months after HDT. For method B we replaced the score of non-responses with the worst 
possible reported score for global QoL in the dataset, which was zero. We found mean score 
differences of -20.4 (95% -35.5;-5.3, p=0.009) before cyclophosphamide priming and -6.4 (95% -22.6; 
9.7, p=0.009) two months after HDT. The results of and the sensitivity analyses method A and B are 
illustrated in figure 3. 
 
Adverse events registered by clinicians and patient-reported toxicities  
In the correlation analysis we compared clinician registered AEs to the patient-reported toxicities for 
the eight toxicity domains of fatigue, nausea and vomiting, dyspnoea, insomnia, appetite loss, 
constipation, diarrhoea and peripheral neuropathy. Since some discrepancies were observed 
between the time points of AE evaluation by clinicians at the study visits and the time points of 
answered questionnaires, time effect correlation analyses were carried out. For constipation we 
observed a statistically significant time effect before cyclophosphamide priming (rho= -0.39; p= 
0.012) and two months after HDT (rho= 0.47; p= 0.005). Also, for diarrhoea, there was a statistically 
significant time effect two months after HDT (rho= -0.34; p= 0.045). Therefore, correlation analyses 
were not performed for constipation at the two follow-up time points and for diarrhoea two months 
after HDT. Overall, poor correlations between the patient-reported toxicity and clinician registered 
AEs for all six toxicities were found with rho values less than 0.4 (Table 3).   
 
Discussion  
Our data demonstrate that MM patients report a clinically relevant reduced HRQoL, when 
clarithromycin is added to the VCD regimen with persisting HRQoL sequelae two months after HDT. 
Using registered toxicities by CTCAE this knowledge could not be concluded from the clinicians´ AE 
evaluation, since they underreported symptomatic toxicities. 
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A limitation of our results is that it is based on an underpowered study due to premature study 
termination with a poor questionnaire completion rate, which made us unable to obtain a valid 
statistical result. Still, when comparing our results to existing literature of HRQoL during induction 
therapy and HDT in MM patients, it is noteworthy that the patients in the clarithromycin group 
reported decreased HRQoL after induction phase (40, 41). Our findings could be explained by the 
pharmacokinetics of bortezomib and clarithromycin. Bortezomib is primarily metabolized by the 
cytochrome P450 enzyme CYP3A4, which is known to be inhibited by clarithromycin. Thus, the 
reduced HRQoL could be a result of increased biological effect of bortezomib in the clarithromycin 
group (13). Clarithromycin has been used in other treatment regimens for MM often in combination 
with Lenalidomide and low-dose dexamethasone, which is found to have favorable toxicity profile 
(14). This discrepancy in AE findings compared to our study supports the explanation of being caused 
by the pharmacokinetic interaction between bortezomib and clarithromycin, when those two drugs 
are administrated in parallel. In the CLAIM study, special precaution was made for the potential risk 
of QT prolongation, ventricular tachycardia and sudden death caused by clarithromycin. Severe 
cardiac disease or QT prolongation was exclusion criteria and ECG was performed at screening, on 
day 4 and before start of VCD cycle 2. If the patient developed QT prolongation (QTc interval > 500 
msec) the clarithromycin/placebo treatment was permanently discontinued. However, no serious 
cardiovascular events were reported during the study (13). 
 
In clinical studies, AEs are traditionally collected as described in CTCAE guideline by clinicians (24). 
Drug efficacy and toxicity profile analyses are included in the process where a given drug is 
considered for approval by the FDA and EMA. In earlier studies comparison of CTCAE and patient-
reported toxicities revealed underreporting of toxicities by the clinicians as compared with patient-
reported toxicities (42, 43). Our study confirmed this discrepancy, thereby emphasizing the 
importance of including HRQoL as an endpoint in clinical trials. Also, it highlights the potentially 
important role of integrating PRO data in real-time safety monitoring in clinical trials as well as in the 
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daily clinical practice (44). A limitation in the interpretation of our results when comparing patient-
reported toxicities and clinician reported AEs is the lack of synchronous registration of toxicities by 
clinicians and patients and the retrospective nature of the analysis. Still, we believe the results are 
convincing since clinicians may tend to underreport AEs (42).  
  
In this current study, we observed that there were non-responses to scheduled questionnaires, 
which is a common challenge in PRO data collection, analysis and interpretation (32, 45, 46). The 
potential consequences of non-responses are decreased precision and power, and more seriously, 
the introduction of bias to the PRO data results, when a patient fails to complete a questionnaire 
because of severe illness or other reasons. It is recommended to design clinical studies with PRO 
data collection with focus on minimization of non-responses and to perform sensitivity analysis to 
explore the impact of non-responses on the PRO data results (46, 47). In our study, more patients in 
the clarithromycin group dropped out early due to serious AEs resulting in a lower questionnaire 
completion compared to patients in the placebo group. Therefore, the analyses performed are 
hypothetically fragile for biased results. We performed analyses to explore the impact of non-
responses of being “missing not at random” (48). We examined the mechanisms of non-responses 
and found that registration of a grade 3-4 AEs was a predictor of non-responses, which confirms that 
some of the non-responses were “missing not at random”. When integrating this information into 
the sensitivity analysis method B it was confirmed that non-responses to questionnaires do impact 
the results of the global QoL domain and that our results might be conservative. However, in the 
sensitivity analysis method A using multiple imputations, we found no impact of non-responses on 
the global QoL results. Limitations in using the multiple imputation method in our study are the low 
sample size and a limited number of patients with grade 3 or 4 AEs reporting a global QoL score. 
Also, the global QoL domain is described as a “distal” measure with limitations in interpretability due 
to greater mediation by personal and environmental characteristics rather than disease and 
treatment related chances (49).  
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  In conclusion, the CLAIM study demonstrated that adding clarithromycin to the VCD regimen in 
MM patients resulted in impaired HRQoL during the VCD induction phase continuing up to two 
months after HDT. The study emphasizes that well-designed randomized, double-blinded and 
placebo-controlled studies with PRO data collection is necessary to determine drug risk benefit 
assessment, and also to test well-known drugs in new combinations. Treatment with clarithromycin 
and VCD in parallel cannot be recommended because of a higher risk of complications and reduced 
HRQoL. The PRO data in the CLAIM study played a key role in explaining the causality link between 
the observed complications and the possible interaction between clarithromycin and bortezomib. In 
addition, the study demonstrates that “real-time” monitoring of patient-reported toxicities as a 
supplement to CTCAE registration should be included in clinical trials. The National Cancer Institute´s 
PRO version of the common terminology criteria for adverse events (PRO-CTCAE) has been validated 
and found feasible in clinical trials for documentation of symptomatic toxicities (50). With this tool, 
PRO data can be incorporated into future clinical cancer studies. Moreover, PRO data will most likely 
be a useful tool in shared treatment decision making in clinical practice. Studies designed to validate 
the use of PRO data in daily practice are warranted.     
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Table 1. Patient demographics 
Characteristics Clarithromycin group 
N=25 
Placebo group 
N=30 
Median age, years (IQR) [range] 64 (55; 67)[40; 70] 62 (55; 66)[37; 70] 
Sex, Male (N) 19 (63.3%) 19 (76.0%) 
Type of myeloma (N) 
IgA myeloma 
  
IgA 3 (12.0%) 
3 (12.0%) 
9 (30.0%) 
9 (30.0%) 
IgG 18 (72.0%) 16 (53.3%) 
Light chain 4 (16.0%) 5 (16.7%) 
Disease stage according to ISS (N)   
I 7 (29.2%) 7 (24.1%) 
II 9 (37.5%) 18 (62.1%) 
III 8 (33.3%) 4 (12.9%) 
Missing 1 1 
Β-2 microglobulin, mg/l (SD)[range] 3.4 (2.4;7.2)[1.6;27.1] 3.6 (2.6;4.6)[1.9;23.4] 
Missing values 1 1 
LDH, units/l (SD)[range] 164 (146;212)[101;267] 178 (158;215)[110;487] 
Missing values 1 3 
Serum creatinine, μmol/l (SD)[range] 81 (69;92)[50;271] 84 (67;97)[45;167] 
WHO performance status scale (N)   
0 13 (52.0%) 17 (56.7%) 
≥1 12 (48.0%) 13 (43.3%) 
IQR; Interquartile range, ISS; International Staging System, LDH; Lactate dehydrogenase,  
WHO; World Health Organization 
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Table 2. Baseline mean scores and standard deviations for the two treatment groups 
Health-related quality of life domains Clarithromycin group 
Mean score (SD)  
N=25 
Placebo group 
Mean score (SD) 
N=30 
EORTC QLQ-C30   
Global QoL 51.7 (25.3) 60.1 (28.0) 
Physical Functioning 64.6 (26.5) 63.9 (30.9) 
Role Functioning 48.6 (35.8) 48.3 (41.9) 
Emotional Functioning 75.7 (17.9) 72.3 (21.2) 
Cognitive Functioning 86.8 (17.0) 81.0 (19.1) 
Social Functioning 78.5 (25.8) 75.0 (35.3) 
Fatigue 39.4 (30.0) 39.5 (29.0) 
Nausea and vomiting 9.0 (12.0) 9.2 (17.0) 
Pain 45.8 (39.7)  55.7 (40.2) 
Dyspnoe 16.7 (19.7) 13.8 (24.4) 
Insomnia 27.8 (27.2) 39.1 (30.9) 
Appetite loss 13.9 (25.9) 16.1 (30.4) 
Constipation 34.7 (37.4) 28.6 (32.3) 
Diarrhoea 8.3 (17.7) 4.8 (11.9) 
Financial difficulties 5.8 (12.9) 7.1 (18.9)  
EORTC QLQ-MY20   
Disease symptoms 32.1 (21.2) 39.8 (30.4) 
Side effects of treatment 13.6 (9.9) 13.4 (13.4) 
Future Perspective 76.8 (34.0) 84.0 (26.7) 
Body image 41.5 (29.1) 41.2 (38.4) 
FACT/GOG-Ntx subscale 8.7 (9.3) 8.0 (8.6) 
EORTC QLQ-C30; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core questionnaire, EORTC 
QLQ-MY20; European Organisation for Research and Treatment of Cancer Multiple Myeloma module, FACT/GOG-Ntx subscale; Functional 
Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity subscale, SD; Standard deviation 
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Table 3. Correlation between registered adverse events by clinicians and patient-reported toxicities 
Patient-reported 
toxicities 
Before cyclophosphamide priming Two months after HDT 
Correlation Correlation 
Rho P-value Rho P-value 
Diarrhoea -0.10 0.53 NA NA 
Constipation NA NA NA NA 
Nausea and vomiting -0.11 0.51 -0.31 0.06 
Fatigue 0.35 0.023 -0.01 0.97 
Insomnia 0.20 0.20 -0.09 0.61 
Peripheral neuropathy 0.29 0.075 -0.02 0.90 
Dyspnoea
2 
- - - - 
Appetite loss 0.02 0.92 0.26 0.13 
1Any grade of toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, patient-reported change 
from baseline above the threshold for minimal important difference calculated by Cohens´ medium effect size (0.5x standard 
deviation of mean baseline score) for the domain, 2Correlation calculation was not possible, since none of the patients had 
dyspnoea registered as an adverse event, NA; correlation analysis was not performed since a statistically significant time effect 
was found. 
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